Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression

• Published in: Human molecular genetics Vol. 33; no. 8; pp. 698 - 708
• Main Authors: Wong, Chao-Jen, Friedman, Seth D, Snider, Lauren, Bennett, Sean R, Jones, Takako I, Jones, Peter L, Shaw, Dennis W W, Blemker, Silvia S, Riem, Lara, DuCharme, Olivia, Lemmers, Richard J F L, van der Maarel, Silvère M, Wang, Leo H, Tawil, Rabi, Statland, Jeffrey M, Tapscott, Stephen J
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 08.04.2024
• Subjects: Biomarkers - metabolism; Clinical Trials as Topic; Disease Progression; Homeodomain Proteins - genetics; Humans; Magnetic Resonance Imaging; Muscle, Skeletal - metabolism; Muscular Dystrophy, Facioscapulohumeral - diagnostic imaging; Muscular Dystrophy, Facioscapulohumeral - genetics; Muscular Dystrophy, Facioscapulohumeral - metabolism; Original; facioscapulohumeral dystrophy; complement; MRI; DUX4
• ISSN: 0964-6906; 1460-2083; 1460-2083
• DOI: 10.1093/hmg/ddae007

Identifying the aberrant expression of DUX4 in skeletal muscle as the cause of facioscapulohumeral dystrophy (FSHD) has led to rational therapeutic development and clinical trials. Several studies support the use of MRI characteristics and the expression of DUX4-regulated genes in muscle biopsies as biomarkers of FSHD disease activity and progression. We performed lower-extremity MRI and muscle biopsies in the mid-portion of the tibialis anterior (TA) muscles bilaterally in FSHD subjects and validated our prior reports of the strong association between MRI characteristics and expression of genes regulated by DUX4 and other gene categories associated with FSHD disease activity. We further show that measurements of normalized fat content in the entire TA muscle strongly predict molecular signatures in the mid-portion of the TA, indicating that regional biopsies can accurately measure progression in the whole muscle and providing a strong basis for inclusion of MRI and molecular biomarkers in clinical trial design. An unanticipated finding was the strong correlations of molecular signatures in the bilateral comparisons, including markers of B-cells and other immune cell populations, suggesting that a systemic immune cell infiltration of skeletal muscle might have a role in disease progression.